CAS 1421373-66-1 Os...

CAS 1421373-66-1 Osimertinib mesylate

CAS 1421373-66-1 Osimertinib mesylate

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price: USD 1000.0000

  • Min.Order :1 Kilogram
  • Purity: 99%
  • Payment Terms : L/C,T/T

Keywords

1421373-66-1 Osimertinib mesylate C29H37N7O5S

Quick Details

  • Appearance:white powder
  • Application:pharma
  • PackAge:as clients needs
  • ProductionCapacity:1|Metric Ton|Day
  • Storage:RT
  • Transportation:sea

Superiority:

Our company was built in 2009 with an ISO certificate.In the past 6 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:
 
 
 
1.Noble Metal Catalysts (Pt.Pd...)
 
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
 
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
 
4.Customs Synthesis
 
 
 
Our advantage:
 
 
 
1. Higest quality and good package
 
2.Fast delivery
 
3.Better payment term
 
4.Fast response to customer  within 6 hours
 
5.Good business credit in Europe ,US ,Japan ,Korea
 
 
 
Anyway ,if you need any chemicals from China ,Henan Tianfu can help you
 

Details:

Osimertinib mesylate Basic information
Product Name: Osimertinib mesylate
Synonyms: Mesylate-AZD9291;Osimertinib Mesylate (Tagrisso, Mereletinib, AZD-9291);Osimertinib d6;N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate;Osimertinib methanesulfonate;Osimertinib (AZD9291) mesylate;AZD-9291 mesylate (Osimertinib mesylate;AZD-9291 mesylate (Osimertinib,Mereletinib)
CAS: 1421373-66-1
MF: C29H37N7O5S
MW: 595.71298
EINECS:
Product Categories: AZD09
Mol File: 1421373-66-1.mol
Osimertinib mesylate Structure
Osimertinib mesylate Chemical Properties
Safety Information
HS Code 29339900
MSDS Information
Osimertinib mesylate Usage And Synthesis
Definition ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer.
Indications The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.
1.Noble Metal Catalysts (Pt.Pd...)
 
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
 
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
 
4.Customs Synthesis
 
 
 
Our advantage:
 
 
 
1. Higest quality and good package
 
2.Fast delivery
 
3.Better payment term
 
4.Fast response to customer  within 6 hours
 
5.Good business credit in Europe ,US ,Japan ,Korea
 
 
 
Anyway ,if you need any chemicals from China ,Henan Tianfu can help you
 
 

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View